Leerink Partnrs Issues Positive Estimate for TMO Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for Thermo Fisher Scientific to $5.64, slightly up from a previous forecast of $5.62.
• JPMorgan Chase increased its target price for Thermo Fisher stock from $600 to $650, maintaining an "overweight" rating.
• Thermo Fisher Scientific's stock closed at $525.08, reflecting a 0.1% increase, with a market cap of $198.28 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a report released on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $5.64 per share for the quarter, up from their previous forecast of $5.62. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q4 2025 earnings at $6.33 EPS, Q2 2026 earnings at $6.06 EPS, Q3 2026 earnings at $6.10 EPS and Q4 2026 earnings at $6.78 EPS.

Several other research firms have also recently issued reports on TMO. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Robert W. Baird increased their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Finally, UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average target price of $589.10.

Thermo Fisher Scientific Stock Up 0.1%

Shares of NYSE TMO opened at $525.08 on Wednesday. The firm's 50 day moving average price is $491.00 and its 200 day moving average price is $448.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $198.28 billion, a P/E ratio of 30.37, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently bought and sold shares of the stock. Mondrian Investment Partners LTD increased its stake in shares of Thermo Fisher Scientific by 146.1% during the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after acquiring an additional 127,357 shares during the period. Caledonia Investments PLC increased its position in shares of Thermo Fisher Scientific by 11.5% during the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company's stock valued at $45,299,000 after purchasing an additional 11,500 shares during the period. Foresight Group Ltd Liability Partnership lifted its holdings in shares of Thermo Fisher Scientific by 3,242.7% in the first quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after buying an additional 56,747 shares during the period. Advisors Capital Management LLC grew its holdings in Thermo Fisher Scientific by 6.7% during the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after acquiring an additional 7,967 shares during the period. Finally, New England Research & Management Inc. lifted its holdings in Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company's stock valued at $1,033,000 after acquiring an additional 567 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 in the last quarter. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.